Tenax Therapeutics, Inc. Common Stock

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 14 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).